%0 Journal Article
%T CyberKnife Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy As First-line Treatments for Imaging-diagnosed Intracranial Meningiomas
%A Hirochika SUZUKI
%A Hiromitsu IWATA
%A Hiroyuki OGINO
%A Michio IWABUCHI
%A Takeshi TAMURA
%A Taro MURAI
%A Yoshihiko MANABE
%A Yoshimasa MORI
%A Yuta SHIBAMOTO
%J Archive of "Neurologia medico-chirurgica".
%D 2017
%R 10.2176/nmc.oa.2017-0115
%X Definitive radiotherapy is an important alternative treatment for meningioma patients who are inoperable or refuse surgery. We evaluated the efficacy and toxicity of CyberKnife-based stereotactic radiosurgery (SRS) and hypofractionated stereotactic radiotherapy (hSRT) as first-line treatments for intracranial meningiomas that were diagnosed using magnetic resonance imaging (MRI) and/or computed tomography (CT). Between February 2005 and September 2015, 41 patients with intracranial meningiomas were treated with CyberKnife-based SRS or hSRT. Eleven of those tumors were located in the skull base. The median tumor volume was 10.4 ml (range, 1.4每56.9 ml). The median prescribed radiation dose was 17 Gy (range, 13每20 Gy to the 61每88% isodose line) for SRS (n = 9) and 25 Gy (range, 14每38 Gy to the 44每83% isodose line) for hSRT (n = 32). The hSRT doses were delivered in 2 to 10 daily fractions. The median follow-up period was 49 months (range, 7每138). The 5-year progression-free survival rate (PFS) for all 41 patients was 86%. The 3-year PFS was 69% for the 14 patients with tumor volumes of ≡13.5 ml (30 mm in diameter) and 100% for the 27 patients with tumor volumes of <13.5 ml (P = 0.031). Grade >2 toxicities were observed in 5 patients (all of them had tumor volumes of ≡13.5 ml). SRS and hSRT are safe and effective against relatively small (<13.5 ml) meningiomas
%K meningioma
%K stereotactic radiosurgery
%K stereotactic radiotherapy
%K hypofractionated stereotactic radiotherapy
%K CyberKnife
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735225/